Cannabinoid agonists indications

Accumulating evidence indicates that endocannabinoids have cannabinoid and non GBR mediated effects in these classical cannabinomimetic actions. CBR-related processes seem also involved in cognition, memory, anxiety, control of appetite, emesis, inflammatory, and immune responses. The cannabinoid agonist may induce biphasic effects for example, hyperactivity at low doses and severe motor deficits at larger doses have been documented. 

There are no approved indications for peripheral cannabinoid agonists for the treatment of pain. Animal models and clinical trials display possible use for inflammatory, visceral, and neuropathic pain. Doses for pain management in humans have yet to be determined. 

Cannabinoid agonists and antagonists that are not stmc-turally related to THC have been synthesised for diverse therapeutic indications. One of them is Rimonabant ... 

Mouse vas deferens (MVD) seems to express CB1 and at least one CB2-like cannabinoid receptor type, as is demonstrated by the presence of CB1 and CB2-like mRNA as well as by data collected from experiments with cannabinoid receptor selective agonists and antagonists (Pertwee, 1999). Furthermore, evidence indicates that a CBl-like receptor exists in vascular endothelium, which upon activation produces significant hypotension (Wagner, 1999). This receptor differs from CB1 in its pharmacological response to some well-characterized cannabimimetics. 

---